Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity
- 1 May 2014
- journal article
- Published by Elsevier in Tuberculosis
- Vol. 94 (3) , 293-298
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Arylamine N-Acetyltransferase 2 (NAT2) Genetic Diversity and Traditional Subsistence: A Worldwide Population SurveyPLOS ONE, 2011
- Role of polymorphic N‐acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment‐induced hepatitisJournal of Gastroenterology and Hepatology, 2011
- Antituberculosis Therapy–Induced Acute Liver Failure: Magnitude, Profile, Prognosis, and Predictors of OutcomeHepatology, 2010
- Role ofCYP2E1gene polymorphisms association with hepatitis risk in Northeast IndiaWorld Journal of Gastroenterology, 2010
- Influence of glutathione S‐transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug‐induced hepatotoxicity in a Caucasian populationLiver International, 2008
- PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage AnalysesThe American Journal of Human Genetics, 2007
- Haploview: analysis and visualization of LD and haplotype mapsBioinformatics, 2004
- RsaI polymorphism at the cytochrome P4502E1 locus and risk of hepatocellular carcinoma.Gut, 1996
- Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.Thorax, 1996
- Criteria of drug-induced liver disordersJournal of Hepatology, 1990